165 related articles for article (PubMed ID: 29285035)
1. Biomarkers of Everolimus Sensitivity in Hormone Receptor-Positive Breast Cancer.
Yi Z; Ma F
J Breast Cancer; 2017 Dec; 20(4):321-326. PubMed ID: 29285035
[TBL] [Abstract][Full Text] [Related]
2. Everolimus in hormone receptor-positive metastatic breast cancer: PIK3CA mutation H1047R was a potential efficacy biomarker in a retrospective study.
Yi Z; Ma F; Liu B; Guan X; Li L; Li C; Qian H; Xu B
BMC Cancer; 2019 May; 19(1):442. PubMed ID: 31088410
[TBL] [Abstract][Full Text] [Related]
3. Phosphorylation of AKT and ERK1/2 and mutations of PIK3CA and PTEN are predictive of breast cancer cell sensitivity to everolimus in vitro.
Citi V; Del Re M; Martelli A; Calderone V; Breschi MC; Danesi R
Cancer Chemother Pharmacol; 2018 Apr; 81(4):745-754. PubMed ID: 29476223
[TBL] [Abstract][Full Text] [Related]
4. PIK3CA mutation, but not PTEN loss of function, determines the sensitivity of breast cancer cells to mTOR inhibitory drugs.
Weigelt B; Warne PH; Downward J
Oncogene; 2011 Jul; 30(29):3222-33. PubMed ID: 21358673
[TBL] [Abstract][Full Text] [Related]
5. K-Ras mutation and amplification status is predictive of resistance and high basal pAKT is predictive of sensitivity to everolimus in biliary tract cancer cell lines.
Yeung Y; Lau DK; Chionh F; Tran H; Tse JWT; Weickhardt AJ; Nikfarjam M; Scott AM; Tebbutt NC; Mariadason JM
Mol Oncol; 2017 Sep; 11(9):1130-1142. PubMed ID: 28544747
[TBL] [Abstract][Full Text] [Related]
6. A new era of improving progression-free survival with dual blockade in postmenopausal HR(+), HER2(-) advanced breast cancer.
Jerusalem G; Bachelot T; Barrios C; Neven P; Di Leo A; Janni W; de Boer R
Cancer Treat Rev; 2015 Feb; 41(2):94-104. PubMed ID: 25575443
[TBL] [Abstract][Full Text] [Related]
7. Molecular Alterations and Everolimus Efficacy in Human Epidermal Growth Factor Receptor 2-Overexpressing Metastatic Breast Cancers: Combined Exploratory Biomarker Analysis From BOLERO-1 and BOLERO-3.
André F; Hurvitz S; Fasolo A; Tseng LM; Jerusalem G; Wilks S; O'Regan R; Isaacs C; Toi M; Burris H; He W; Robinson D; Riester M; Taran T; Chen D; Slamon D
J Clin Oncol; 2016 Jun; 34(18):2115-24. PubMed ID: 27091708
[TBL] [Abstract][Full Text] [Related]
8. Everolimus: targeted therapy on the horizon for the treatment of breast cancer.
Barnett CM
Pharmacotherapy; 2012 Apr; 32(4):383-96. PubMed ID: 22461124
[TBL] [Abstract][Full Text] [Related]
9. Everolimus in postmenopausal, hormone receptor-positive advanced breast cancer: summary and results of an austrian expert panel discussion.
Gnant M; Greil R; Hubalek M; Steger G
Breast Care (Basel); 2013 Aug; 8(4):293-9. PubMed ID: 24415983
[TBL] [Abstract][Full Text] [Related]
10. The PI3K/AKT/mTOR pathway in breast cancer: targets, trials and biomarkers.
Paplomata E; O'Regan R
Ther Adv Med Oncol; 2014 Jul; 6(4):154-66. PubMed ID: 25057302
[TBL] [Abstract][Full Text] [Related]
11. Clinical implications of recent studies using mTOR inhibitors to treat advanced hormone receptor-positive breast cancer.
Arena F
Cancer Manag Res; 2014; 6():389-95. PubMed ID: 25336989
[TBL] [Abstract][Full Text] [Related]
12. mTOR inhibitors in the treatment of breast cancer.
Vinayak S; Carlson RW
Oncology (Williston Park); 2013 Jan; 27(1):38-44, 46, 48 passim. PubMed ID: 23461041
[TBL] [Abstract][Full Text] [Related]
13. Potential role for mammalian target of rapamycin inhibitors as first-line therapy in hormone receptor-positive advanced breast cancer.
Beck JT
Onco Targets Ther; 2015; 8():3629-38. PubMed ID: 26675495
[TBL] [Abstract][Full Text] [Related]
14. Activation of phosphoinositide 3-kinase/Akt/mechanistic target of rapamycin pathway and response to everolimus in endocrine receptor-positive metastatic breast cancer - A retrospective pilot analysis and viewpoint.
Bajpai J; Ramaswamy A; Chandrasekharan A; Mishra S; Shet T; Gupta S; Badwe RA
South Asian J Cancer; 2017; 6(3):102-105. PubMed ID: 28975114
[TBL] [Abstract][Full Text] [Related]
15. Everolimus: a new hope for patients with breast cancer.
Sendur MA; Zengin N; Aksoy S; Altundag K
Curr Med Res Opin; 2014 Jan; 30(1):75-87. PubMed ID: 24050600
[TBL] [Abstract][Full Text] [Related]
16. Everolimus in the treatment of hormone receptor-positive breast cancer.
Chavez-MacGregor M; Gonzalez-Angulo AM
Expert Opin Investig Drugs; 2012 Dec; 21(12):1835-43. PubMed ID: 22994502
[TBL] [Abstract][Full Text] [Related]
17. Combined treatment with everolimus and fulvestrant reversed anti-HER2 resistance in a patient with refractory advanced breast cancer: a case report.
Sun B; Ding L; Wu S; Meng X; Song S
Onco Targets Ther; 2016; 9():3997-4003. PubMed ID: 27445490
[TBL] [Abstract][Full Text] [Related]
18. The predictive value of KRAS, NRAS, BRAF, PIK3CA and PTEN for anti-EGFR treatment in metastatic colorectal cancer: A systematic review and meta-analysis.
Therkildsen C; Bergmann TK; Henrichsen-Schnack T; Ladelund S; Nilbert M
Acta Oncol; 2014 Jul; 53(7):852-64. PubMed ID: 24666267
[TBL] [Abstract][Full Text] [Related]
19. Phase II randomized study of neoadjuvant everolimus plus letrozole compared with placebo plus letrozole in patients with estrogen receptor-positive breast cancer.
Baselga J; Semiglazov V; van Dam P; Manikhas A; Bellet M; Mayordomo J; Campone M; Kubista E; Greil R; Bianchi G; Steinseifer J; Molloy B; Tokaji E; Gardner H; Phillips P; Stumm M; Lane HA; Dixon JM; Jonat W; Rugo HS
J Clin Oncol; 2009 Jun; 27(16):2630-7. PubMed ID: 19380449
[TBL] [Abstract][Full Text] [Related]
20. Targeting the mammalian target of rapamycin pathway with everolimus: implications for the management of metastatic breast cancer.
Ng VC; Johnson JJ; Cuellar S
J Oncol Pharm Pract; 2015 Dec; 21(6):433-42. PubMed ID: 24964967
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
